CINECA IRIS Institutional Research Information System

BAIETTO, LORENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.086
EU - Europa 4.371
AS - Asia 1.358
SA - Sud America 79
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 23
OC - Oceania 20
Totale 12.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.014
DK - Danimarca 1.261
CN - Cina 792
IT - Italia 478
DE - Germania 411
IE - Irlanda 356
SE - Svezia 348
FR - Francia 323
FI - Finlandia 241
GB - Regno Unito 225
UA - Ucraina 210
KR - Corea 153
AT - Austria 151
SG - Singapore 138
PL - Polonia 121
ES - Italia 72
CA - Canada 60
IN - India 60
VN - Vietnam 58
JP - Giappone 57
NL - Olanda 55
BE - Belgio 32
BR - Brasile 24
ID - Indonesia 22
CL - Cile 21
ZA - Sudafrica 21
AU - Australia 20
RU - Federazione Russa 20
CO - Colombia 17
EU - Europa 16
CZ - Repubblica Ceca 14
PT - Portogallo 13
TW - Taiwan 12
AR - Argentina 10
IR - Iran 10
MX - Messico 10
PK - Pakistan 10
TH - Thailandia 9
AP - ???statistics.table.value.countryCode.AP??? 7
HK - Hong Kong 7
TR - Turchia 7
CH - Svizzera 6
QA - Qatar 5
SN - Senegal 5
UZ - Uzbekistan 5
BA - Bosnia-Erzegovina 4
EG - Egitto 4
HR - Croazia 4
PE - Perù 4
SK - Slovacchia (Repubblica Slovacca) 4
BG - Bulgaria 3
KZ - Kazakistan 3
NO - Norvegia 3
RO - Romania 3
RS - Serbia 3
SI - Slovenia 3
CR - Costa Rica 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
MA - Marocco 2
PH - Filippine 2
PY - Paraguay 2
SA - Arabia Saudita 2
BD - Bangladesh 1
BT - Bhutan 1
EC - Ecuador 1
GR - Grecia 1
IM - Isola di Man 1
KE - Kenya 1
LI - Liechtenstein 1
MD - Moldavia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
RE - Reunion 1
TN - Tunisia 1
Totale 12.974
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.490
Chandler 625
Beijing 503
Dublin 357
Fairfield 294
Houston 274
Villeurbanne 227
Ashburn 214
Wilmington 199
Torino 173
Dearborn 171
Seattle 159
Woodbridge 158
Jacksonville 148
Nyköping 148
Princeton 147
Vienna 147
Medford 133
Warsaw 112
Redwood City 102
Singapore 88
Cambridge 86
Pisa 53
Fremont 50
New York 45
Boardman 41
Guangzhou 37
Milan 37
Boston 36
Toronto 33
Shanghai 29
Dong Ket 27
Munich 27
Nanjing 26
Brussels 23
Verona 22
Jakarta 21
Philadelphia 20
Falls Church 19
Hangzhou 15
Hefei 15
Jinan 15
Chicago 14
Helsinki 14
Madrid 14
Norwalk 14
Paris 14
San Diego 14
Turin 14
Nürnberg 13
Phoenix 13
Santiago 13
Los Angeles 12
Portland 12
Amsterdam 11
Columbus 11
Kunming 10
Nanchang 10
Santa Clara 10
Washington 10
Edinburgh 9
Tokyo 9
Barcelona 8
Denver 8
Des Moines 8
Fuzhou 8
London 8
Bogotá 7
Brno 7
Dallas 7
Wuhan 7
Cincinnati 6
Indianapolis 6
Isfahan 6
Lachine 6
Pittsburgh 6
Pune 6
Rochester 6
Rome 6
Shenyang 6
Sydney 6
São Paulo 6
Taipei 6
Winterville 6
Delhi 5
Doha 5
Grafing 5
Kharkiv 5
Knoxville 5
Montreal 5
Mountain View 5
Ottawa 5
Poznan 5
Seoul 5
Tianjin 5
Ankara 4
Brisbane 4
Burlington 4
Cape Town 4
Changsha 4
Totale 8.008
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics of linezolid during extracorporeal membrane oxygenation 877
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 332
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 301
Ceftriaxone bone penetration in patients with septic non-union of the tibia 291
A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics? 282
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 276
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). 270
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 250
Anidulafungin for Candida glabrata Infective Endocarditis 243
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 239
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 230
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 229
Ultra Performance Liquid Chromatography PDA Method for Determination of Tigecycline in Human Plasma. 217
Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH 212
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 176
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 174
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 172
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 172
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 170
Single-Nucleotide Polymorphisms of ABCB1 Gene Influence Intracellular Concentrations of Dasatinib. 166
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 162
Effect of multidrug-resistant gene polymorphisms on daptomycin concentrations: preliminary results 162
Farmacocinetica dell’anidulafungina in pazienti con fibrosi cistica, trapianto epatico e emodiafiltrazione: dati preliminari. 161
Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D 161
Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. 159
PHISIOLOGIC VARIABLES AND PHARMCOKINETICS IMIPENEM DURING ENLP. A SINGLE CENTER TRANSPLANTATION EXPERIENCE 155
Development and validation of a new method to simultaneously quantify triazoles in plasma spotted on dry sample spot devices and analysed by HPLC-MS. 154
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 154
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 153
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 151
Role of Cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 149
Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia 148
Influenza dei polimorfismi C3453T, C1236T, G2677T/A del gene MDR1 sulle concentrazioni plasmatiche di daptomicina 148
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 147
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 147
UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells 144
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 144
Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. 142
Farmacocinetica della caspofungina in pazienti sottoposti a trapianto epatico. 139
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 139
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 137
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 137
Development and validation of an UPLC-PDA method to quantify daptomycin in human plasma and in dried plasma spots. 136
Therapeutic drug monitoring of intracellular anti-infective agents. 136
Prophylaxis drug monitoring of itraconazole and voriconazole in the paediatric onco-haematological setting 134
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 132
How effective are the use of DBS and DPS as tools to encourage widespread therapeutic drug monitoring? 132
Role of cytochrome P450 in imatinib pharmacokinetics: clinical relevance of inhibitors/inducers concomitant use 130
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T 130
Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. 130
Is Maraviroc a substrate for SLCO1B1? 129
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 128
Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study 110
ABCB1 3435C>T e CYP2B6 516G>T possono predire le concentrazioni plasmatiche ottimali di Nevirapina 94
Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs 87
Ceftriaxone cerebrospinal fluid levels in adult patients with meningoencephalitis 86
High four weeks’ entecavir plasma concentration is a negative predictor of HBV DNA drop after three months of therapy 83
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted Atazanavir 83
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T predict higher plasma concentrations of nevirapine (NVP). 81
Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots 81
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. 76
Pharmacogenomic influence on sepsis outcome in critically ill patients 75
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 74
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. 73
Pharmacokinetics of high dosage of linezolid in two morbidly obese patients-authors' response 73
Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. 72
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir 69
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma 67
Anidulafungin pharmacokinetic evaluation in a cohort of patients 66
Evaluation of 7 different resistence interpretation algoritms and their derived gentotypic inhibitory quotients for the prediction of 48-week virological response to darunavir-based salvage regimens 65
Pharmacokinetics of high dosage of linezolid in two morbidly obese patients 64
Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs 64
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV 64
Pharmacokinetic of caspofungin in patients with invasive candidiasis 63
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon 63
Pharmacokinetics of caspofungin in patients with candidaemia 63
Cut-off values of ribavirin trough concentration for sustained virological response and for hematological toxicity in HCV/HIV-co-infected patients treated with RBV and Pegylated Interferon 63
A new UPLC-MS-MS method to quantify first line antituberculosis agents in plasma spotted on dried sample spots device (DSSD) 61
A Simple and Fast Method for Quantification of Ertapenem using Meropenem as Internal Standard in Human Plasma in a Clinical Setting 59
Le concentrazioni plasmatriche di ATV boostato ed unboosted correlano con il polimorfismo 63396C>T del pregnane X receptor. 59
PXR 63396C>T is a predictor of boosted and unboosted atazanavir plasma concentrations 59
A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma 58
A probable drug-to-drug interaction between voriconazole and haloperidol in a slow metabolizer of CYP2C19 58
Single nucleotide polymorphisms of ABCB1 gene influence on intracellular concentrations of dasatinib. 56
Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. 56
Physical and Chemical Stability of Urapidil in 0.9% Sodium Chloride in Elastomeric Infusion Pump 56
Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients 54
A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients 54
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. 53
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. 51
Daptomycin plasma and CSF levels in patients with external ventricular drain (EVD)-related ventriculo-meningitis (VM) 51
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene 49
Single Nucleotide Polymorphisms of ABCB1 Gene Influence Daptomycin Pharmacokinetics in Adult Patients. [A-1769] 49
Caspofungin: is standard dosing optimal or inadequate? Pharmacokinetic description in a cohort of patients 48
Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients 48
PHARMACOKINETICS OF RALTEGRAVIR IN THE CLINICAL SETTING 47
Usefulness of therapeutic drug monitoring of posaconazole in haematological adult patients 46
Totale 13.315
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.412
article - articoli 0
book - libri 0
conference - conferenze 12.737
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.149
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.652 0 0 69 217 328 529 239 110 128 250 338 444
2020/20211.505 346 67 42 94 86 62 86 48 111 129 110 324
2021/20223.004 289 257 273 308 226 269 321 276 194 80 272 239
2022/20231.954 211 100 37 150 228 501 126 157 195 39 144 66
2023/2024764 87 125 42 45 61 108 30 55 14 31 63 103
2024/2025119 16 60 43 0 0 0 0 0 0 0 0 0
Totale 13.628